SARS-CoV-2 and the safety margins of cell-based biological medicinal products [post]

Jens Modrof, Astrid Kerschbaum, Maria Farcet, Daniela Niemeyer, Victor Corman, Thomas Kreil
2020 unpublished
With the pandemic emergence of SARS-CoV-2, the exposure of cell substrates used for manufacturing of medicines has become a possibility. Cell lines used in biomanufacturing were thus evaluated for their SARS-CoV-2 susceptibility, and the detection of SARS-CoV-2 in culture supernatants was tested by routine adventitious virus testing of fermenter harvest.
doi:10.22541/au.159121409.99363381 fatcat:sycgiyorbja4hnyypufz26gn74